Type 2 diabetes complications are associated with liver fibrosis independent of hemoglobin A1c.

[1]  Sunil Kumar,et al.  Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics. , 2022, Life sciences.

[2]  V. de Lédinghen,et al.  Impact of type 2 diabetes on the accuracy of non-invasive tests of liver fibrosis with resulting clinical implications. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  Miyoung Choi,et al.  Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis , 2022, Gut and liver.

[4]  Z. Younossi,et al.  Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease , 2022, The American journal of gastroenterology.

[5]  Z. Younossi,et al.  Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD , 2021, Hepatology communications.

[6]  E. Tapper,et al.  Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis , 2021, Digestive Diseases and Sciences.

[7]  V. Wong,et al.  Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis , 2021, Gut.

[8]  M. Lai,et al.  The Presence of Diabetes Impacts Liver Fibrosis and Steatosis by Transient Elastography in a Primary Care Population. , 2021, Annals of hepatology.

[9]  H. Trivedi.  An Algorithmic Approach to NAFLD Screening: From PCP to Specialist , 2020, ACG case reports journal.

[10]  L. Beretta,et al.  Elevated Glycated Hemoglobin Is Associated With Liver Fibrosis, as Assessed by Elastography, in a Population‐Based Study of Mexican Americans , 2020, Hepatology communications.

[11]  H. Trivedi,et al.  The Impact of Non-alcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. , 2020, The American journal of medicine.

[12]  M. Connelly,et al.  Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD , 2020, Hepatology communications.

[13]  V. Wong,et al.  Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study , 2020, Hepatology.

[14]  American Diabetes Association.  1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[15]  D. Thorburn,et al.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[16]  M. Stepanova,et al.  Epidemiology of chronic liver diseases in the USA in the past three decades , 2019, Gut.

[17]  P. Tandon,et al.  Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care , 2019, Hepatology communications.

[18]  N. Sattar,et al.  Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts , 2019, BMC Medicine.

[19]  R. Andrade,et al.  Development and Validation of Hepamet Fibrosis Scoring System-a Simple, Non-invasive Test to Identify Patients With Nonalcoholic Fatty liver Disease With Advanced Fibrosis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  J. Talwalkar,et al.  Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real‐World Data From a Large U.S. Claims Database , 2018, Hepatology.

[21]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[22]  M. Allison,et al.  Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis , 2016, The American Journal of Gastroenterology.

[23]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[24]  Z. Younossi,et al.  Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL) , 2016, Health and Quality of Life Outcomes.

[25]  H. El‐Serag,et al.  Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  H. El‐Serag,et al.  Nonalcoholic Fatty Liver Disease is Underrecognized in the Primary Care Setting , 2015, The American Journal of Gastroenterology.

[27]  T. Saibara,et al.  Glycemic Variability Is an Independent Predictive Factor for Development of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease , 2013, PloS one.

[28]  S. Pol,et al.  FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.